Plaintiffs Move for Creation of Farxiga Diabetes Drug MDL

WASHINGTON, D.C. — Plaintiffs with claims against makers of the Type 2 diabetes drug Farxiga have asked the U.S. Judicial Panel on Multidistrict Litigation to create a centralized docket for their cases, just months after they were excluded from the creation of an Invokana MDL.

The petition, filed Feb. 3, requests that the JPML transfer 18 cases, pending in six different federal courts, to a single federal judge in New York, Pennsylvania or Illinois.

According to the plaintiffs, all of the lawsuits similarly allege that Farxiga, an SGLT2 inhibitor used to treat Type 2 Diabetes, causes a variety of …